文献速递血栓与止血

皮下注射糖基聚乙二醇化重组凝血因子Ⅷ(N8-GP)的临床前药代动力学与生物分布及人体药代动力学预测模型的建立

Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model.
PubMed 文献 · J Thromb Haemost · 2018-05-10

N8-GP是用于治疗A型血友病的半衰期延长重组凝血因子Ⅷ。本研究在F8基因敲除小鼠和食蟹猴中评估皮下注射N8-GP的药代动力学、止血效果及注射部位分布,并建立人体药代动力学预测模型。结果表明皮下N8-GP在动物模型中具有良好药代动力学特征并从注射部位消失,模型预测每日皮下给药12.5 IU/kg可使95%的重型A型血友病患者FVIII谷浓度达到2.5-10%。

要点

  • 皮下注射N8-GP在F8-KO小鼠的生物利用度为24%、半衰期14小时,在食蟹猴为26%、15小时。
  • F8-KO小鼠单次或多次给药后48-72小时注射部位仅检测到极少量N8-GP,随时间从储库消失。
  • 模型预测每日皮下注射12.5 IU/kg可使95%重型A型血友病患者FVIII谷浓度达2.5-10%。

核心结论

  • 皮下注射N8-GP可能为A型血友病提供有效的预防治疗,一项I期临床试验正在进行以研究这一可能性。

研究设计与样本

  • 在F8基因敲除小鼠和食蟹猴中评估皮下注射N8-GP的药代动力学,并建立A型血友病患者的人体药代动力学预测模型。
  • 在F8-KO小鼠尾静脉出血模型中评估止血效果,并通过时间荧光成像和免疫组化评估注射部位分布与吸收。

主要发现

  • 皮下注射N8-GP在F8-KO小鼠的生物利用度为24%、一级吸收速率常数为0.094 h-1、半衰期为14 h;在食蟹猴分别为26%、0.33 h-1和15 h。
  • 在F8-KO小鼠中观察到皮下注射N8-GP对失血量呈剂量依赖性效应。
  • F8-KO小鼠单次或多次给药后48-72小时注射部位仅检测到极少量N8-GP,皮下注射N8-GP局限于注射部位周围皮肤并随时间从储库消失。
  • 药代动力学模型预测每日皮下注射N8-GP 12.5 IU/kg可使95%的重型A型血友病患者FVIII谷浓度达到2.5-10%。

临床怎么用

  • 作者认为皮下注射N8-GP可能提供有效的A型血友病预防治疗,一项I期临床试验正在进行以研究这一可能性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials N8-GP is an extended half-life recombinant factor VIII (FVIII) for the treatment of hemophilia A. Subcutaneous (SC) FVIII dosing might reduce the treatment burden of prophylaxis. SC N8-GP has a favorable PK profile in animal models and disappears from skin injection sites. Combined animal (SC) and clinical (IV) data suggest that daily SC dosing may provide prophylaxis. SUMMARY: Background N8-GP is an extended half-life recombinant factor VIII (FVIII) for the treatment of hemophilia A. Subcutaneous administration of FVIII may reduce the treatment burden of prophylaxis; however, standard FVIII products have low bioavailability after subcutaneous dosing in animals. Objective To evaluate the pharmacokinetics, effectiveness and local distribution of subcutaneously administered N8-GP in preclinical models and predict the human pharmacokinetic (PK) profile. Methods The pharmacokinetics of subcutaneously administered N8-GP were evaluated in FVIII knockout (F8-KO) mice and cynomolgus monkeys; a human PK prediction model in hemophilia A patients was developed. The hemostatic effect was evaluated in a tail vein bleeding model in F8-KO mice. The injection-site distribution and absorption of subcutaneously administered N8-GP were assessed in F8-KO mice by the use of temporal fluorescence imaging and immunohistochemistry. Results Subcutaneously administered N8-GP had a bioavailability, a first-order absorption rate and a half-life, respectively, of 24%, 0.094 h-1 and 14 h in F8-KO mice, and 26%, 0.33 h-1 and 15 h in cynomolgus monkeys. A dose-dependent effect of subcutaneously administered N8-GP on blood loss was observed in mice. A minimal amount of N8-GP was detected at the injection site 48-72 h after single or multiple dose(s) in F8-KO mice. Subcutaneously administered N8-GP was localized to the skin around the injection site, with time-dependent disappearance from the depot. PK modeling predicted that subcutaneously administered N8-GP at a daily dose of 12.5 IU kg-1 will provide FVIII trough levels of 2.5-10% in 95% of patients with severe hemophilia A. Conclusions Subcutaneously administered N8-GP may provide effective hemophilia A prophylaxis. A phase I clinical trial is underway to investigate this possibility.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Rode F, Almholt K, Petersen M, et al. Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model. J Thromb Haemost. 2018. PMID: 29582559. doi:10.1111/jth.14013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。